Madrigal Pharmaceuticals: A "Best in Class" Biotech Buy
February 17, 2022 at 10:23 AM EST
One of the few broadly positive binary events in biotechnology of late, Madrigal’s best-in-class NASH compound is well on its way with de-risked, late-stage clinical results.
